Multidisciplinary

Top Medical News
Pearl Toh, 40 minutes ago
Inhaled treprostinil significantly improves exercise capacity in terms of 6-minute walking distance (6MWD) over 16 weeks compared with placebo in patients with pulmonary hypertension associated with interstitial lung disease (ILD), according to the INCREASE trial presented at ATS 2020.
Jairia Dela Cruz, an hour ago
Eating higher amounts of white rice raises the risk of diabetes, and this association is especially pronounced in South Asia, a study has found. Meanwhile, in other regions of the world, the risk is modest or inconsequential.
2 hours ago
Curcuma longa (CL), or turmeric, extract appears to be effective for knee pain but has shown no impact on knee effusion–synovitis or cartilage composition, suggests a recent study.
Stephen Padilla, 3 hours ago
Ten countries in the Asia Pacific region, with six coming from Southeast Asia (SEA), have topped the ranking of nations that successfully suppressed the novel coronavirus disease (COVID-19) pandemic, according to The Lancet COVID-19 Commission statement on the 75th session of the United Nations (UN) General Assembly.
4 hours ago
The associations of anxiety, depression, and chronic inflammation with aortic pulse wave velocity (aPWV) and systolic blood pressure (SBP) indicate the first evidence of a brain–gut–vascular axis and new potential targets for treatment in patients with Crohn’s disease (CD), reveals a study.
Audrey Abella, 5 hours ago
The application of cold atmospheric plasma (CAP) therapy to diabetic foot ulcers (DFUs) led to significant acceleration of wound healing process compared with placebo treatment, the German KaltplasmaWund trial has shown.
Tristan Manalac, 6 hours ago
For patients with type 1 diabetes (T1D), switching to faster insulin aspart may improve glycated haemoglobin (HbA1c), time-in-range (TIR), and time in hyperglycaemia, without posing serious hypoglycaemia risks, according to a new study.
Special Reports
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Audrey Abella, 21 Sep 2020
Single-inhaler triple-therapy (SITT) comprising FF/UMEC/VI* is preferred over dual therapies (DT) or multiple-inhaler (MI) TT for managing COPD**, according to data presented at ERS 2020.
Pearl Toh, 16 Sep 2020
Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.
16 Sep 2020
XOFLUZA – Baloxavir marboxil 20 mg and 40 mg FC tab
16 Sep 2020
OZEMPIC – Semaglutide 1.34 mg/mL soln for inj
16 Sep 2020
GALVUS MET – Vidagliptin, metformin HCl 50 mg/500 mg, 50 mg/850 mg and 50 mg/1,000 mg FC tab
16 Sep 2020
COSYREL – Bisoprolol fumarate, perindopril arginine 5 mg/5 mg, 5 mg/10 mg and 10 mg/10 mg FC tab
Conference Reports
Roshini Claire Anthony, 24 Sep 2020

For patients with unresectable malignant pleural mesothelioma (MPM), nivolumab plus ipilimumab in the first-line setting demonstrated greater overall survival (OS) than standard-of-care (SoC) platinum chemotherapy, interim analysis of the phase III CheckMate743 trial revealed.

Roshini Claire Anthony, 23 Sep 2020

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.

Pearl Toh, 23 Sep 2020
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 22 Sep 2020

Treatment with the DPP 1* inhibitor brensocatib prolonged time to exacerbation and reduced exacerbation rates in patients with non-cystic fibrosis bronchiectasis, according to the phase II WILLOW** study presented at ERS 2020.

Audrey Abella, 22 Sep 2020
The first-in-class oral tyrosine kinase inhibitor (TKI) masitinib demonstrated a positive benefit-risk profile over a sustained period in patients with severe persistent asthma regardless of baseline eosinophil level, with the greatest benefit seen among those with the highest oral corticosteroid (OCS) dependency, according to data presented at ERS 2020.
Roshini Claire Anthony, 21 Sep 2020

Daily albumin infusion to achieve serum albumin levels of 30 g/L did not reduce the risk of infection, renal dysfunction, or mortality in individuals with acute decompensated cirrhosis, according to results of the ATTIRE* study presented at ILC 2020.

Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
CME Modules
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download